| HOME >> BIOLOGY >> TECHNOLOGY |
WAYNE, Pa. and LIVERPOOL, England, Oct. 13 /PRNewswire/ -- Molecular Detection Inc. (MDI), a company developing Detect-Ready™ assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that its Detect-Ready MRSA assay has received its first independent validation in a study conducted at St. George's Healthcare NHS Trust, a leading teaching hospital in the UK. The study results were presented this week at HIS 2010, the Seventh International Conference of the Hospital Infection Society(1).
In a comparative study of the Detect-Ready assay and two other widely used PCR-based MRSA screening tests, the St. George's researchers confirmed that the performance of the Detect-Ready MRSA assay was better than or equivalent to Becton Dickinson's GeneOhm™ MRSA ACP Assay and Roche's LightCycler® MRSA Advanced Test. Based on the results of this study, MDI's Detect-Ready is now used as the molecular assay of choice in the MRSA screening programs at St George's.
"Following this comparative study, St. George's has adopted the Detect-Ready MRSA kit for routine MRSA screening in our intensive care unit (ICU), as a result of the high sensitivity and specificity we observed and the kits' ease-of-use and cost-effectiveness," said Dr. Cassie Pope, Clinical Scientist of St. George's.
"The Detect-Ready MRSA kit provides a number of advantages, including software that provides non-subjective interpretation and straight-forward reporting. The inclusion of multiple gene targets in the Detect-Ready MRSA test appears to minimize false positive results, reducing both unnecessary resource deployment and the inconvenience to patients wrongly labeled as MRSA positive," said Kay Capaldi, Chief Biomedical Scientist of St George's.
"St. George's is one of the most respected research hospitals in the UK, so we are especially pleased to receive their independent validation confirming
'/>"/>
| SOURCE Molecular Detection Inc. Copyright©2010 PR Newswire. All rights reserved |